TMS CO.,LTD. reports Q4 results, advances

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on February 13, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

TMS CO.,LTD. reports Q4 results, advances drug development

Source disclosure: February 13, 2026 TMS Co.,Ltd. [4891.T] TOKYO, Feb 13 (Pulse News Wire) – TMS CO.,LTD. (4891.T) reported its fiscal year ending December 2025 results, showing a reduction in operating expenses compared to initial forecasts. Operating losses decreased by --¥71 million percent year-over-year, despite a ten-month reporting period due to the shift in the fiscal year-end from February to December. The company also highlighted progress in clinical trials for TMS-007 (JX